Get the Stockscreener App
5.11
4.66%
-0.25
After Hours:
5.11
Immucell Corp stock is traded at $5.11, with a volume of 427.
It is down -4.66% in the last 24 hours and down -5.55% over the past month.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
See More
Previous Close:
$5.36
Open:
$5.02
24h Volume:
427
Relative Volume:
0.03
Market Cap:
$40.03M
Revenue:
$23.84M
Net Income/Loss:
$-3.81M
P/E Ratio:
-10.22
EPS:
-0.5
Net Cash Flow:
$-713.00K
1W Performance:
-5.28%
1M Performance:
-5.55%
6M Performance:
+36.27%
1Y Performance:
-0.39%
1-Day Range:
$5.02
$5.11
1-Week Range:
$4.89
$5.36
52-Week Range:
$3.34
$5.82
Immucell Corp Stock (ICCC) Company Profile
Name
Immucell Corp
Sector
Industry
Phone
(207) 878-2770
Address
56 EVERGREEN DR, PORTLAND, ME
Compare ICCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCC
Immucell Corp
|
5.11 | 40.03M | 23.84M | -3.81M | -713.00K | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immucell Corp Stock (ICCC) Latest News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving Average – What’s Next? - Defense World
ImmuCell Settles Insurance Claim for Production Contamination Events - Defense World
ImmuCell settles insurance claim for production losses - Investing.com
ImmuCell Secures $426,587 Additional Insurance Settlement for Production Contamination Issues - StockTitan
ImmuCell Announces Strong Preliminary Sales Results for Q4 and Full Year 2024 - Defense World
ImmuCell Sales Surge 52% to Record $26.5M as Production Hits Full Capacity - StockTitan
ImmuCell (NASDAQ:ICCC) Shares Pass Above 200 Day Moving Average – Here’s What Happened - Defense World
ImmuCell announces executive transition with part-time agreement By Investing.com - Investing.com South Africa
ImmuCell announces executive transition with part-time agreement - Investing.com
Zacks Initiates Coverage of ImmuCell With Neutral Recommendation - Yahoo Finance
The Zacks Analyst Blog Highlights Amazon.com, Stryker, Lam Research and ImmuCell - Yahoo Finance
Top Research Reports for Amazon, Stryker & Lam Research - Yahoo Finance
ImmuCell amends agreement with Norbrook Labs - Investing.com
ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges - MSN
ImmuCell Third Quarter 2024 Earnings: US$0.086 loss per share (vs US$0.12 loss in 3Q 2023) - Yahoo Finance
ImmuCell Corporation (NASDAQ:ICCC) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: ImmuCell reports recovery and strong demand for Q3 2024 - Investing.com
ICCCImmucell Corp Latest Stock News & Market Updates - StockTitan
ImmuCell Q3 Sales Jump 11% to $6M, Nine-Month Revenue Surges 51% Despite Net Loss | ICCC Stock News - StockTitan
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024 - StockTitan
ImmuCell reports 11% sales boost in third quarter - Investing.com
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024 - StockTitan
ImmuCell amends lease terms and by-laws - Investing.com
Healthcare Stock Performance - Yahoo Finance
IMMUCELL CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
ImmuCell Second Quarter 2024 Earnings: US$0.20 loss per share (vs US$0.18 loss in 2Q 2023) - Yahoo Finance
ImmuCell Corporation (NASDAQ:ICCC) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: ImmuCell reports growth amid operational challenges - Investing.com
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024 - StockTitan
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024 - StockTitan
ImmuCell (ICCC) Scheduled to Post Earnings on Wednesday - Defense World
ImmuCell stock touches 52-week low at $3.92 amid market challenges - Investing.com
ImmuCell Corp hits 52-week low, trading at $4.05 - Investing.com
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024 - StockTitan
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® - StockTitan
ImmuCell Corporation (ICCC) Q1 2024 Earnings Call Transcript - Seeking Alpha
Breeding innovation: Rarebreed grows out of Maine’s animal-health hub - Mainebiz
Bovine Mastitis Treatment System Market Analysis : US, Germany, France, India, ChinaForecast 2024-2028 - Technavio
Top 20 Animal Health Companies in the World - Insider Monkey
‘Unleashing’ growth: Maine's emerging ‘Silicon Valley for animal health’ - Mainebiz
No. 1 in the Northeast: Maine startup business is region’s fastest-growing, says Inc. - Press Herald
Biotechnology now employs nearly 10,000 workers in Maine - Press Herald
ImmuCell plans second expansion in three years as demand grows - Mainebiz
Portland-based biotech ImmuCell posts 45% sales increase for Q4 - Mainebiz
ImmuCell Corp (ICCC) CEO Michael Brigham Q4 2021 Results Earnings Call Transcript - Seeking Alpha
ImmuCell hires Commercial Research & Technical Services Veterinarian - Bovine Veterinarian
Portland’s ImmuCell targeted by New York law firm over FDA setback - Press Herald
Guidance Calendar as of Oct 9th - Benzinga
Portland-based ImmuCell reports sales increase, advances toward product release - Mainebiz
ImmuCell (NASDAQ:ICCC) Stock Quotes, Forecast and News Summary - Benzinga
Immucell Corp Stock (ICCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):